cccOrthogon Therapeutics Raises an Additional $11M Financing for Its BK Virus Antiviral Drug Program

  CANTON, Mass. - Friday, 17. April 2026 AETOSWire Print 

Establishing an innovative class of polyomavirus antivirals spanning BK and JC virus indications

(BUSINESS WIRE) -- Orthogon Therapeutics today announced the closing of a follow-on $11 million financing, bringing its total capital raised to $36 million. This financing supports the continued advancement of its first-in-class drug against BK polyomavirus. BK virus infections are a major cause of complications in transplant patients, with no approved treatments.

The company is pioneering an oral therapy that addresses the full spectrum of BK infection, from early reactivation through systemic spread and onset of severe disease. By targeting viral proteins previously considered inaccessible to small molecule drugs, Orthogon is advancing a solution where other therapeutic modalities have fallen short.

Orthogon’s lead asset uniquely targets the viral capsid protein (VP1), delivering potent antiviral effect at the site of viral replication. The intracellular activity leads to sustained control of viral infection across BK variants and related human polyomaviruses, particularly in transplant patients, where viral persistence drives disease.

“This is not a conventional antiviral setting. We built this program to meet the realities of transplant care,” said Ali H. Munawar, Ph.D., CEO of Orthogon Therapeutics. “These patients are treated within a narrow balance of immunosuppression, organ function, and high pill burden. We designed around those constraints, arriving at a candidate profile that we’re excited to take into development.”

In parallel, Orthogon has published findings examining hundreds of patient-derived BK virus sequences, showing that the virus carries pre-existing diversity at antibody-binding regions and that it replicates beyond the reach of circulating antibodies. These studies explain the limited clinical benefit observed with neutralizing antibodies, challenges that Orthogon’s drug is designed to overcome.

The program draws on Orthogon’s portfolio of novel small molecules directed at each of the two viral proteins: the VP1 capsid and large T antigen (LTAg), a capability that has eluded the field for decades. The program will be featured at leading transplant and virology meetings in 2026, building on findings presented at the ASN in 2025.

Alongside its core focus on polyomaviruses, Orthogon is advancing programs in additional areas of unmet need in transplant-associated infections.

About BK and polyomaviruses:

BK virus (BKV) is among the most widespread chronic viral infections in humans. A member of the polyomavirus family, BKV establishes a lifelong infection in 80–90% of healthy adults worldwide. Reactivation occurs in the kidneys of nearly half of all solid organ and stem cell transplant recipients, leading to severe complications and graft loss. Other human polyomaviruses, including JC virus and Merkel cell polyomavirus, cause fatal progressive multifocal leukoencephalopathy (PML) and aggressive Merkel cell carcinoma, respectively.

About Orthogon Therapeutics:

Orthogon is a polyomavirus-focused biotech built on a proprietary discovery platform that fuses structure-based drug design with deep biophysical interrogation of viral proteins, unlocking targets long considered undruggable. The company is headquartered in Greater Boston with a research branch in Leuven, Belgium. To learn more visit www.orthogontherapeutics.com

Orthogon Therapeutics LLC is an independent, privately held research & development (R&D) company affiliated with the Pledge Therapeutics discovery engine. More info on www.pledge-tx.com

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260417911548/en/

Permalink

https://www.aetoswire.com/en/news/1704202654392

Contacts

Ali H. Munawar, Ph.D.

amunawar@orthogontherapeutics.com

1-339-502-8643

Maria Martin

mmartin@pledge-tx.com

1-339-502-8630

BlackBerry, JVCKENWOOD and SK Telecom Join Sisvel POS Patent Pool as Licensors

  LUXEMBOURG - Friday, 17. April 2026 AETOSWire Print 

(BUSINESS WIRE) -- The new Sisvel Point of Sale (POS) patent pool, announced on 1 April, has added three new licensors in the last two weeks. BlackBerry, JVCKENWOOD and SK Telecom have joined founding licensors Huawei, LG Electronics and Nokia in making their patents available for license through the programme.

Sisvel POS covers 2G, 3G, 4G and 5G technologies. It is the first joint licensing programme to address point of sale devices – a category of product that has leveraged cellular connectivity to transform customer payment processing.

Participating patent owners make their relevant standards essential patents (SEPs) available on FRAND terms, simplifying access to essential IP rights for POS device makers. Early participation incentives for licensors are available until mid-May. Parties interested in joining the pool are encouraged to contact Sisvel as soon as possible.

“BlackBerry, JVCKENWOOD and SK Telecom are first-rate cellular innovators. I am pleased they have chosen to become part of Sisvel POS,” says programme manager Sven Törringer. “Since announcing the pool just over two weeks ago we have received a tremendous volume of interest from the market. We are confident of welcoming additional patent owners into the programme, so watch this space.”

About Sisvel

Sisvel is driven by a belief in the importance of collaboration, ingenuity and efficiency to bridge the needs of patent owners and those who wish to access their technologies. In a complex and constantly evolving marketplace, our guiding principle is to create a level playing field through the development and implementation of flexible, accessible, commercialisation solutions.

Sisvel | We Power Innovation

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260416519765/en/

Permalink

https://www.aetoswire.com/en/news/1704202654391

Contacts

Media Contact

Giulia Dini

Executive Head of Brand

Tel: +34 93 131 5570

giulia.dini@sisvel.com

 

Multi-Color Corporation Announces Confirmation of Plan of Reorganization

 Company Expects to Emerge from Prepackaged Chapter 11 in Coming Weeks With Significantly Deleveraged Balance Sheet Including Approximately $3.8 Billion Reduction in Outstanding Funded Debt

Significant New Money Investment Will Establish Strong Liquidity Position to Support Long-Term Growth and Investment

(BUSINESS WIRE)--Multi-Color Corporation (“MCC” or the “Company”), a global leader in prime label solutions, today announced that the United States Bankruptcy Court for the District of New Jersey (the “Court”) has confirmed the Company’s prepackaged plan of reorganization (the “Plan”). MCC expects to emerge from prepackaged Chapter 11 in the coming weeks.

Under the terms of the Plan, MCC will complete a comprehensive restructuring transaction that significantly deleverages the Company’s balance sheet and recapitalizes the business. The restructuring reduces net debt by approximately $3.8 billion, reduces annualized cash interest expense by more than $330 million, and extends long‑term debt maturities to 2033. In addition, MCC will receive a significant $889 million investment from CD&R and a group of MCC’s existing secured lenders. Post-emergence, the Company expects to have more than $500 million of available liquidity to support long-term growth and investment.

“Today’s confirmation marks the near-completion of our financial restructuring process, positioning MCC to emerge as an even more resilient company,” said Hassan Rmaile, President & Chief Executive Officer of MCC. “With the support of our financial stakeholders, MCC will emerge with a significantly deleveraged balance sheet and liquidity available to support our go-forward operations, invest in innovation, and continue delivering the high-quality label solutions that our customers depend on. I am grateful to our teammates, customers, and suppliers for their steadfast commitment and support throughout this process, and we look forward to the opportunities ahead.”

Plan confirmation follows a successful mediation and global settlement among every major constituency in MCC’s prepackaged Chapter 11 cases, with more than 99% of voting stakeholders accepting MCC’s prepackaged Chapter 11 plan. This global settlement is in addition to the support previously obtained through the restructuring support agreement entered into prior to the commencement of MCC’s prepackaged Chapter 11 cases in January 2026.

With court approval in hand, MCC expects to receive the proceeds from the significant new common and preferred equity investment and complete its financial restructuring in the coming weeks.

For more information on MCC’s restructuring, including access to Court documents, please visit www.veritaglobal.net/MCC. Stakeholders with questions can contact Verita, the Company’s claims and noticing agent, at (866) 967-1788 (U.S./Canada toll free) or +1 (310) 751-2688 (International) or submit an inquiry to www.veritaglobal.net/MCC/inquiry. Additional information is also available at MCCForward.com.

Advisors

Kirkland & Ellis LLP and Cole Schotz P.C. are serving as legal counsel, Evercore Group LLC is serving as investment banker, AlixPartners LLP is serving as financial advisor, Quinn Emanuel Urquhart & Sullivan LLP is serving as special counsel to the Special Committee of LABL, Inc.’s Board of Directors, and FGS Global is serving as strategic communications advisor to the Company. Debevoise & Plimpton LLP and Latham & Watkins LLP are serving as legal counsel to CD&R and Moelis & Company LLC is serving as its financial advisor. Milbank LLP and PJT Partners serve as legal counsel and financial advisor, respectively, to the ad hoc group of secured creditors.

About MCC

Multi-Color Corporation (MCC) is a global leader in prime label solutions, providing innovative and sustainable solutions to some of the world’s most recognizable brands across a broad range of consumer-oriented end categories. MCC is committed to delivering the world’s best label solutions for their customers to build their brands and add value to the communities in which they operate.

Forward-Looking Statements

This press release contains certain forward-looking statements with respect to the financial condition, results of operations and business of MCC and its subsidiaries and certain plans and objectives with respect thereto. These forward-looking statements can be identified by the fact that they do not relate only to historical or current facts. Forward-looking statements often use words such as “anticipate”, “target”, “expect”, “enable”, “estimate”, “intend”, “plan”, “goal”, “believe”, “hope”, “aims”, “continue”, “will”, “may”, “should”, “would”, “could”, or other words of similar meaning. These statements are based on assumptions and assessments made by the Company and its perception of historical trends, current conditions, future developments and other factors. By their nature, forward-looking statements involve risk and uncertainty, because they relate to events and depend on circumstances that will occur in the future and the factors described in the context of such forward-looking statements in this document could cause actual results and developments to differ materially from those expressed in or implied by such forward looking statements. Although it is believed that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct, and you are therefore cautioned not to place undue reliance on these forward-looking statements which speak only as at the date of this document. The Company does not assume any obligation to update or correct the information contained in this document (whether as a result of new information, future events or otherwise), except as may be required by applicable law. There are several factors which could cause actual results to differ materially from those expressed or implied in forward-looking statements.

Among the factors that could cause actual results to differ materially from those described in the forward‑looking statements are changes in the global, political, economic, business, competitive, market, supply chain, and regulatory forces, future exchange and interest rates, changes in tax rates and any future business combinations or dispositions, uncertainties and costs related to the RSA and the Chapter 11 process, including, among others, potential adverse effects of the Chapter 11 process on the Company’s liquidity and results of operations, including with respect to its relationships with its customers, distribution partners, suppliers, and other third parties; employee attrition and the Company’s ability to retain senior management and other key personnel due to the distractions and uncertainties inherent in the Chapter 11 process; the impact of any cost reduction initiatives; any other legal or regulatory proceedings; the Company’s ability to obtain operating capital, including complying with the restrictions imposed by the terms and conditions of any debtor-in-possession financing, such as the financing mentioned herein; the length of time that the Company will operate under Chapter 11 protection; the timing of any emergence from the Chapter 11 process; and the risk that any plan of reorganization resulting therefrom may not be implemented at all. Please see the Joint Prepackaged Plan of Reorganization of MultiColor Corporation and its Debtor Affiliates Pursuant to Chapter 11 of the Bankruptcy Code [Docket No. 17] and the Disclosure Statement Relating to the Joint Prepackaged Plan of Reorganization of MultiColor Corporation and its Debtor Affiliates Pursuant to Chapter 11 of the Bankruptcy Code [Docket No. 18], (each as may be amended, modified or supplemented) for additional considerations and risk factors associated with the company’s Chapter 11 process. Nothing in this press release is intended as a profit forecast or estimate for any period and no statement in this press release should be interpreted to mean that the financial performance for the Company for the current or future financial years would necessarily match or exceed its historical results. Further, this press release is not intended to and does not constitute and should not be construed as, considered a part of, or relied on in connection with any information or offering memorandum, security purchase agreement, or offer, invitation or recommendation to underwrite, buy, subscribe for, otherwise acquire, or sell any securities or other financial instruments or interests or any other transaction.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260416782928/en/

Permalink

https://www.aetoswire.com/en/news/1704202654384

Contacts

MEDIA CONTACT

FGS Global for MCC

mcclabel@fgsglobal.com

Guidewire Launches ProNavigator, Embedding Expert AI Insights into Insurance Workflows

 Embedded directly in policy and claims workflows, ProNavigator surfaces the right role-specific intelligence at the moment of decision, helping underwriters, claim adjusters, and customer service representatives work faster, smarter, and with confidence.

(BUSINESS WIRE) -- Guidewire (NYSE: GWRE) today announced the launch of Guidewire ProNavigator, an AI assistant embedded in its core applications, InsuranceSuite and InsuranceNow. Introduced in the company’s latest release, Palisades, ProNavigator delivers expert guidance, enables confident decision-making, and accelerates time to value for Property and Casualty (P&C) insurers, equipping underwriters, claims adjusters, billing specialists, and customer service representatives with role-specific AI insights that are governed, secure, and context-aware.

ProNavigator empowers insurers to:

Scale expertise with dependable, accurate information that’s grounded in the insurer’s unique source material, including citations

Maintain strict governance and security models by enforcing role-based access controls (RBACs) to ensure only authorized users can access specific documents or sources

Trust the decisions made and maintain control with audit trails and a human-in-the-loop experience in the flow of work

Reduce time-to-value and the long-term maintenance burden with a production-ready experience from day one, which stays current, release after release

“ProNavigator gives insurance professionals exactly the right information, right when they need it,” said Amy Mollin, Vice President, Product Management at Guidewire. “By embedding it directly into InsuranceSuite and InsuranceNow, we're enabling frontline teams to quickly access accurate answers and confidently make better decisions. It’s AI that just works, helping insurers move smoothly from evaluating AI to successfully adopting it in everyday operations.”

Palisades Empowers Insurers to Achieve Operational Excellence

Expanded functionality in Palisades gives developers the ability to safely leverage their preferred AI tools to create unique digital experiences. It also drives greater precision across critical financial processes, and gives pricing teams the agility to respond quickly to shifting market conditions.

New capabilities enable insurers to:

Accelerate delivery of digital experiences that adhere to the Jutro design system and libraries with Jutro Developer Assistant*

Improve accuracy from payment to refund reconciliation with enhanced funds tracking, including complete audit trails for finance and service teams

Enjoy more seamless electronic claim exchanges with brokers, bureaus, and insurers with a redesigned claims adjuster experience tailored specifically for the operational needs of the London Market

Improve workers’ compensation claim and renewal outcomes with a new experience template offering self-service access to financial data and predictive intel on litigation and claims outcomes

Access consistent, real-time pricing and quoting across all channels with PricingCenter rating capabilities for personal and high-volume commercial lines now available inside PolicyCenter

For more detailed information, please visit the ProNavigator webpage, the Palisades webpage, and the Palisades release blog.

Certain release features may not be available in all regions.

*Indicates product feature is available for Early Access customers only.

About Guidewire

Guidewire is the platform P&C insurers trust to engage, innovate, and grow efficiently. More than 570 insurers in 43 countries, from new ventures to the largest and most complex in the world, rely on Guidewire products. With core systems leveraging data and analytics, digital, and artificial intelligence, Guidewire defines cloud platform excellence for P&C insurers.

We are proud of our unparalleled implementation record, with 1,700+ successful projects supported by the industry’s largest R&D team and SI partner ecosystem. Our marketplace represents the largest partner community in P&C, where customers can access hundreds of applications to accelerate integration, localization, and innovation.

For more information, please visit www.guidewire.com and follow us on X and LinkedIn.

NOTE: For information about Guidewire trademarks, visit https://www.guidewire.com/legal-notices.

Cautionary Language Concerning Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding the general availability of features, programs, services, and tools related to Palisades mentioned in this press release (including, without limitation, ProNavigator, PricingCenter, and Jutro Developer Assistant). These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as “expect,” “anticipate,” “should,” “believe,” “hope,” “target,” “project,” “goals,” “estimate,” “potential,” “predict,” “may,” “will,” “might,” “could,” “intend,” variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond Guidewire’s control. Guidewire’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in Guidewire’s most recent Forms 10-K and 10-Q filed with the Securities and Exchange Commission as well as other documents that may be filed by Guidewire from time to time with the Securities and Exchange Commission. In particular, the following factors, among others, could cause results to differ materially from those expressed or implied by such forward-looking statements: quarterly and annual operating results may fluctuate more than expected; seasonal and other variations related to our customer agreements and related revenue recognition may cause significant fluctuations in our results of operations, Annual Recurring Revenue (“ARR”), and cash flows; our reliance on sales to and renewals from a relatively small number of large customers for a substantial portion of our revenue and ARR; our making long-term pricing commitments in our customer contracts based on available information and estimates about our future costs that may change; our ability to successfully manage our business model, including achieving market acceptance of our cloud-based services and products and the costs related to cloud operations, cybersecurity, product development, and services; the timing, success, and number of professional services engagements and the billing rates and utilization of our professional services employees and contractors; the impact of global events (including, without limitation, ongoing global conflicts, inflation, high interest rates, economic volatility, bank failures and associated financial instability, and supply chain issues) on our employees, our business, and the businesses of our customers, system integrator (“SI”) partners, and vendors; data security breaches of our cloud-based services and products or unauthorized access to our employees’ or our customers’ data; our competitive environment and changes thereto; issues in the development and use of artificial intelligence and machine learning combined with an uncertain regulatory environment; use of AI by our workforce may present risks to our business; errors or failures in our products or services, as well as service interruptions or failure of the third-party service providers we rely on; our services revenue produces lower gross margins than our license, subscription and support revenue; our product development and sales cycles are lengthy and may be affected by factors outside of our control; the impact of new regulations and laws (including, without limitation, security, privacy, artificial intelligence and machine learning, tax regulations and laws, and accounting standards); assertions by third parties that we violate their intellectual property rights; weakened global economic conditions may adversely affect the P&C insurance industry, including the rate of information technology spending; our ability to sell our services and products is highly dependent on the quality of our professional services and SI partners; the risk of losing key employees; the challenges of international operations, including changes in foreign exchange rates; and other risks and uncertainties. Past performance is not indicative of future results. The forward-looking statements included in this press release represent Guidewire’s views as of the date of this press release. Guidewire anticipates that subsequent events and developments will cause its views to change. Guidewire undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Guidewire’s views as of any date subsequent to the date of this press release.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260416283036/en/

Permalink

https://aetoswire.com/en/news/1604202654369

Contacts

Melissa Cobb

Director, Public Relations

Guidewire Software, Inc.

+1.650.464.1177

mcobb@guidewire.com

 

Skild AI Acquires Zebra Technologies' Robotics Automation Business

 Any robot. Any warehouse. One brain. Now at scale.

 

(BUSINESS WIRE)--Skild AI today announced the acquisition of Zebra Technologies' Robotics Automation business, including its Symmetry Fulfillment orchestration platform.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260415518240/en/

The Skild Brain — the industry's first omnibodied AI software designed to operate without prior knowledge of a robot's exact body form — can control any robot, across any task, in any warehouse environment. With Zebra's battle-tested Symmetry orchestration platform, it now has the infrastructure to deploy and orchestrate entire fleets of Skild Brain-powered robots at enterprise scale.

From Fragmented Automation to Orchestrated Intelligence: Warehouse robots today are programmed task-by-task, locked to specific hardware. Change the robot, and you're largely starting from scratch. The Skild Brain was built to break that dependency — generalizing across humanoids, mobile robots, and industrial arms without retraining. Symmetry, already proven in some of the world's most demanding logistics environments, coordinates those robots in real time alongside frontline workers. Every new deployment feeds the Skild Brain's data flywheel, making it smarter across every environment it operates in.

Together, they form something that hasn't existed before: one intelligent layer that can run an entire warehouse, regardless of what robots are in it.

Turning Existing Warehouses Into Symphonies of Autonomy: Logistics operators no longer need to engineer their warehouse around their robots and deal with several partners — each providing one fragment of the automated solution. Skild AI’s acquisition of Zebra’s Robotics Automation business will create the first organization that can provide a full end-to-end automation solution for warehouses: humanoids for pick-place, robotic dogs for inspection, robotic arms for packing, AMRs for material movement and an orchestration layer to control them all.

Skild AI grew from zero to approximately $30M in revenue in just a few months in 2025 and is now positioned to scale enterprise deployments at a pace that was not previously possible. Skild AI will build end-to-end solutions for warehouses, accelerating the pace of deployments at a rate unheard of in the current AI robotics industry.

In their words:

"Warehouse automation remains deeply fragmented today, with classical approaches falling short in most real-world scenarios — a fundamental barrier to achieving true operational efficiency. Tearing down and rebuilding warehouses to suit pre-programmed robots is simply not a viable economic solution. By combining Zebra's human-robot orchestration platform with Skild AI's omnibodied brain, we are set to transform what end-to-end automation looks like in warehouses that exist today. Zebra's orchestration layer brings humans into the fold alongside Skild AI's vision of 'any robot, any task, one brain' — turning warehouses into living symphonies of human and machine autonomy." — Deepak Pathak, CEO, Skild AI

“Lack of automated grasping and complex manipulation continues to slow down warehouses. The Skild Brain in conjunction with the Zebra’s tried and tested person-to-goods solution will turn warehouses into hubs of hyper-efficiency.” — Abhinav Gupta, President, Skild AI

About Skild AI : Founded in 2023, Skild AI builds a general-purpose foundation model for robotics. Backed by SoftBank Group, NVIDIA Ventures, Macquarie Capital (entities administered by Macquarie Capital), Jeff Bezos, Sequoia Capital, Lightspeed, Coatue, Felicis, and others, the company is valued at over $14 billion. Offices in Pittsburgh, the San Francisco Bay Area, and Bengaluru.

Follow some of Skild AI’s latest news on LinkedIn, X.com, Facebook and YouTube.

Follow Zebra on its Blog, LinkedIn, Facebook, X, Instagram and YouTube.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260415518240/en/

Permalink

https://www.aetoswire.com/en/news/1604202654357

Contacts

For press inquiries: press@skild.ai or comms@zebra.com

 

Ferring Pharmaceuticals and Gallup Announce Landmark Global Public Attitudes Study on Fertility and Family-Building

 WASHINGTON - 

Ferring Global Fertility Monitor will gather data from a representative sample in 70 countries as a part of the Gallup World Poll

Consultation to gather expert opinion on high impact questions begins this year

The project aims to provide data and evidence to inform demography-related policymaking against a backdrop of total fertility rates dropping below replacement levels in many countries worldwide, with the U.S. reporting its lowest on record in the latest federal data released last week1

 

(BUSINESS WIRE)--Ferring Pharmaceuticals and Gallup today announced the Ferring Global Fertility Monitor, a global study on the factors influencing people’s fertility choices, at the 2026 Annual Convening of Semafor World Economy.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260415305082/en/

The Ferring Global Fertility Monitor is grounded in the recognition that declining global fertility rates are an increasingly significant public policy topic, with rates already well below replacement level in many countries. Rolled out as part of the Gallup World Poll, it will provide policymakers with robust, globally comparable data on the social, economic, cultural, and structural factors shaping fertility choices. By integrating these insights with people’s lived experiences, well-being, and aspirations, the Monitor supports more responsive, inclusive, and human-centred approaches to demographic change.

Jean-Frédéric Paulsen, Chairman of the Board of Directors and Chief Executive Officer of Ferring Pharmaceuticals, said: “As a company committed to supporting people on their fertility journey, we see the global debate on demographic change as one of the defining issues of our time. Around the world, questions about the future shape of populations are intensifying, yet the data needed to fully understand these shifts, and their implications, remains far too limited. This project has the potential to transform that landscape. By strengthening the global evidence base, we can deepen understanding of what is happening and why, helping governments, health systems and communities plan for a more sustainable future.”

Jon Clifton, Chief Executive Officer of Gallup, said: “We spend a lot of time debating falling fertility and birth rates, but surprisingly little time asking people why. This initiative changes that, using nationally representative data, collected consistently at a scale no one has attempted before across 70 countries."

In 2026, the Ferring Global Fertility Monitor will be developed through an expert consultation and research process designed to identify critical evidence gaps in how fertility decisions are understood across countries. A cognitively tested questionnaire will then enter the 2027 Gallup World Poll and run as a biannual tracker. When complete, the Monitor will represent one of the most comprehensive global data and evidence bases to date on how people think about parenthood, and what helps or hinders them from realising those aspirations.

The Gallup World Poll is the world’s largest private survey infrastructure, collecting annual data from around 140 countries. All data are nationally representative of the adult population and collected either via face-to-face or telephone interviewing. The World Poll collects data on a wide range of topics, all of which speak to how people’s lives are going.

About Gallup

Gallup delivers analytics and advice to help leaders and organisations solve their most pressing problems. Combining more than 85 years of experience and a global reach, Gallup knows more about the attitudes and behaviours of employees, customers, students and citizens than any other organisation in the world.

About Ferring Pharmaceuticals

Ferring Pharmaceuticals a privately owned, specialty biopharmaceutical group committed to building families and helping people live better lives. We are leaders in reproductive medicine with a strong heritage in gastroenterology and urology, and are at the forefront of innovation in uro-oncology gene therapy. Ferring was founded in 1950 and employs more than 7,500 people worldwide. The company is headquartered in Saint-Prex, Switzerland, and has operating subsidiaries in more than 50 countries which market its medicines in over 100 countries.

Learn more at www.ferring.com, or connect with us on LinkedIn, Instagram and YouTube.

Reference

1National Vital Statistics System; Births: Provisional Data for 2025; Report No.43; April 2026: Vital Statistics Rapid Release, Number 043 (April 2026) (Accessed April 2026)

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260415305082/en/

Permalink

https://www.aetoswire.com/en/news/1604202654368

Contacts

For more information, please contact

Ferring Pharmaceuticals

EU - Matthew Worrall, +44 7442 271 811, matthew.worrall@ferring.com

EU - Mary Knight, +44 7747 758 437, mary.knight@ferring.com

US - Lisa Perdomo, +1 (862) 341-9820, lisa.perdomo@ferring.com

Gallup

US - Riada Asimovic Akyol, +1 (202) 715-3095, Riada_akyol@gallup.com

 

Galderma Launches New Alastin Regenerating Skin Nectar with TriHex+™, Powered by Its Next-Generation TriHex Technology® Regenerative Platform

 ZUG, Switzerland - 

Regenerating Skin Nectar has long played a central role in the peri-procedural skin journey as part of Alastin’s dedicated procedure support portfolio, enhancing the body’s natural processes for removing damaged collagen and elastin while creating an optimal environment for new, healthy collagen and elastin production — visibly improving how the skin prepares for, responds to, and recovers from procedures.

With the addition of our proprietary Octapeptide‑45, Regenerating Skin Nectar with TriHex+™ introduces an advanced formulation that builds on the original Tri-Hex Technology® foundation, while further supporting the skin’s natural production of new collagen, elastin, and high‑molecular‑weight hyaluronic acid (HA).1

The new formulation also helps reinforce skin structure, restore skin barrier, and support long-term skin longevity.

This innovation underscores Galderma’s commitment to advancing peri-procedural skincare and empowering providers with science-based solutions designed to deliver exceptional aesthetic and procedural outcomes.

 

(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the launch of Regenerating Skin Nectar with TriHex+™, the newest innovation from Alastin, a leader in peptide-based regenerative skincare.

As a pioneer in peri‑procedural skincare, Alastin helped establish the category with the original Regenerating Skin Nectar — one of the first products specifically developed to prepare the skin before cosmetic procedures, complement procedural outcomes, and visibly support a smoother, accelerated recovery.

For more than a decade, it has served as a foundational peri-procedural product used by aesthetic providers to improve skin readiness and enhance treatment response. Today, among physicians who offer the brand, Alastin is their preferred peri-procedural skincare choice, and it remains the only product in this category with published clinical data demonstrating the benefits of preconditioning the skin prior to a procedure.

The new and enhanced Regenerating Skin Nectar with TriHex+™ builds on this foundation with an advanced formulation designed to help visibly improve how the skin prepares for, responds to, and recovers from procedures. It complements a broad range of aesthetic and surgical procedures such as facelifts, microneedling, laser resurfacing, chemical peels, and radiofrequency ablation, among others.

Regenerating Skin Nectar with TriHex+™ is the second product to feature the next-generation TriHex+™ platform, following the successful launch of Restorative Skin Complex with TriHex+™. TriHex Technology® uniquely combines proprietary peptide components that help clear aged, damaged collagen and elastin while simultaneously supporting the production of new, healthy collagen and elastin — a dual mechanism that underpins its regenerative approach. TriHex+™ is the next evolution of this technology. The addition of proprietary Octapeptide‑45 advances this activity by supporting the skin’s natural production of high‑molecular‑weight HA, a critical component of skin structure and resilience, and working synergistically with TriHex Technology® to further enhance production of collagen, elastin, and HA. This reinforces the skin’s underlying structural integrity, including the dermal-epidermal junction (DEJ), and supports the skin’s response to procedural stress in ways that contribute to more consistent outcomes and long-term skin longevity.

 

“Galderma continues to deepen the understanding of extracellular matrix remodeling, which is now recognized as a key driver of skin aging and longevity. Our new TriHex+™ formulation represents the evolution of our regenerative platform, focusing on key proteins and membranes that influence how the skin responds to procedural stress at a structural level. This innovation reflects our continued commitment to developing science-driven solutions that not only aid in procedural outcomes, but also support a more resilient skin recovery.”

 

ALAN D. WIDGEROW, MBBCH, MMED, FCS, FACS

CHIEF SCIENTIFIC OFFICER, GALDERMA

HEAD, SKIN SCIENCE CENTER FOR INNOVATION

 

Peer-reviewed clinical studies support the use of Regenerating Skin Nectar with TriHex+™ as a foundational peri‑procedural product. In a randomized, double‑blind facelift pre‑conditioning study, 100% of patients showed visible improvements in key extracellular matrix (ECM) markers—including collagen, elastin, and high‑molecular‑weight HA—alongside reductions in solar elastosis and a stronger, more defined DEJ.2 The improvement in DEJ definition is clinically meaningful, as DEJ integrity helps skin better withstand mechanical and thermal stress during procedures.3,4 Additional evaluations demonstrated statistically significant improvements in skin barrier function as early as 30 minutes post-application, with continued improvement through day 14, alongside increased skin hydration observed from day 3.² Clinical grading and photography showed visibly improved healing responses, including reduced appearance of erythema (redness), edema (swelling), and crusting. Split‑face microneedling evaluations also demonstrated improved tolerability compared with exosome-based products.5 These findings reinforce the role of peri-procedural skincare in optimizing overall treatment outcomes.

The formulation is water-free, preservative-free, and bacteriostatic, allowing for use immediately following procedures. This enables early integration into post-procedure care when the skin is most vulnerable and requires products that will not irritate or disrupt healing.

 

“In my practice, patients are looking for treatments that deliver strong results while minimizing downtime. Alastin Regenerating Skin Nectar has helped support that balance by preparing the skin ahead of procedures, visibly improving how it responds during treatment, and promoting a more efficient recovery afterward. With TriHex+™, the clinical data demonstrates it supports advanced improvements in hydration, barrier function, and recovery response — factors I prioritize to help deliver more consistent, high-quality outcomes for my patients.”

 

NAZANIN SAEDI, MD

BOARD-CERTIFIED DERMATOLOGIST

DERMATOLOGY ASSOCIATES OF PLYMOUTH MEETING

 

Galderma will launch Regenerating Skin Nectar with TriHex+™ in the United States this month. For an extended initial period, the product will be available exclusively through authorized Alastin skincare providers and dispensed directly through medical aesthetic practices, including dermatology and plastic surgery offices, and medical spas. Galderma is working to expand availability to additional international markets where Alastin is present.

About Alastin

Alastin by Galderma is the leader in peri-procedural regenerative skincare, offering innovative, scientifically proven, and clinically tested products. The Alastin Skincare portfolio provides a comprehensive collection of cutting-edge formulas designed specifically for peri-procedural use, as well as daily skincare regimens, all powered by proprietary peptides and innovative, clinically meaningful, science-backed ingredients designed to amplify the skin’s own natural regenerative abilities. With more than 60 international dermatological publications and 20 patents granted, Alastin is one of the most clinically studied professional-grade skincare brands.

About Galderma

Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

References

Widgerow AD, et al. J Drugs Dermatol. 2024 May 1;23(5):347-352.

Jalian HR, et al. J Cosmet Dermatol. 2025;24(12):e70556.

Roig-Rosello E, Rousselle P. Biomolecules. 2020;10:1607.

Fisher G, Rittié L. J Cell Commun Signal. 2018;12:401–411.

Widgerow AD, Ziegler ME, Shafiq F, et al. J Dermat Cosmetol. 2024;8(3):87–92.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260415545576/en/

Permalink

https://www.aetoswire.com/en/news/1604202654366

Contacts

For further information:

Christian Marcoux, M.Sc.

Chief Communications Officer

christian.marcoux@galderma.com

+41 76 315 26 50

Viviana Wiewall

Head of U.S. Communications

viviana.wiewall@galderma.com

+1 786 451 7740

Céline Buguet

Franchises and R&D Communications Director

celine.buguet@galderma.com

+41 76 249 90 87

Emil Ivanov

Head of Strategy, Investor Relations, and ESG

emil.ivanov@galderma.com

+41 21 642 78 12

Jessica Cohen

Investor Relations and Strategy Director

jessica.cohen@galderma.com

+41 21 642 76 43

Richard Harbinson

Corporate Communications Director

richard.harbinson@galderma.com

+41 76 210 60 62